Navigation Links
Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Date:3/17/2008

Clinical study to commence late this year

MELBOURNE, Australia, March 17 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease.

Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) that affect over 150,000 patients in the USA and more than twice that worldwide. Over 95% of PV cases and over 50% of ET and primary and secondary myelofibrosis cases are believed to be caused by a mutation in the JAK2 kinase enzyme. This renders the kinase permanently active and leads to the overproduction of particular blood cells.

No specific treatments exist for these diseases and untreated progressive disease can lead to leukemia or myelofibrosis. CYT387 possesses an excellent selectivity profile against a large panel of kinases and other pharmacological targets. It also has excellent pharmacokinetics including oral bioavailability and in preclinical models has a promising safety profile.

CYT387 has also recently shown efficacy in a well-validated in-vivo model of myeloproliferative disorders in studies in the laboratory of physician- scientist Michael Deininger MD PhD at Oregon Health & Science University Cancer Institute, USA. Results showed a profound effects on abnormal blood counts and clinical symptoms of MPDs in mice that were dosed orally.

Dr Deininger said, "We are highly encouraged by Cytopia's compound in this model of myeloproliferative disease which clearly indicates significant improvement of symptoms and disease remission. The favorable data from this animal model augers well for activity of the compound in the clinic."

The compound will now be progres
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
2. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
6. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the 38 th Annual Deutsche Bank ... on May 30, 2013, at 1:30 p.m. EDT. ... are invited to listen to the live discussion via ... it directly at http://www.media-server.com/m/p/f7bj3q84 . A recorded replay ...
(Date:5/20/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") today announced, ... (the "Announcement"), a firm intention to increase its offer ... to $12.50 per share in cash.  The increased offer ... due diligence.  The $1.00 per share net cash right ... to waive down the Acceptance Threshold for the increased ...
(Date:5/20/2013)... Sequent Medical, Inc. announced today that it ... family of WEB ® Aneurysm Embolization Devices, and ... in select neurovascular centers in Europe.  The SL family ... enable physicians to treat a broader range of aneurysms ... are made possible by further advancement of Sequent Medical,s ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2
... pleased to announce the publication of a new syndicated ... report covers the use of biologics for the treatment ... quarterly series, focuses on current and future use of ... of the key brands, barriers to broader usage, sales ...
... Nov. 2, 2010 Cypin Production, a leader in ... and China, is pleased to announce the already-high interest ... Strategies and Partnership Models for R&D Success". ... at the Hub Cira Centre in Philadelphia, is being ...
Cached Medicine Technology:Rheumatoid Arthritis Patient Share of Actemra Projected to Exceed Patient Share of Cimzia and Simponi Among the Medicare Population 2Cypin Production Announces Launch of U.S./China BioPharma Conference: 2
(Date:5/20/2013)... Mombo from Comfort & Harmony ... US Lactation Consultant Association (USLCA) May 2nd – 5th. ... other health professionals. , The USLCA annual conference ... discover and learn about the latest trends in lactation. ... nursing pillows, which new mothers use to help support ...
(Date:5/20/2013)... 2013 Mirena IUD lawsuit ... litigation recently established in U.S. District Court, Southern District ... to court records, the litigation’s first Status Conference was ... Plaintiff’s leadership positions were discussed. So far, at ... District of New York, all of which allege that ...
(Date:5/20/2013)... Co-founder of Atlanta SEO company EverSpark Interactive, ... 5th International INVEST Domaining & Internet Marketing Conference in ... and independent individuals from around the world to discuss ... The 2013 conference will take place at the Mexico ... to 21. A networking city tour day is on ...
(Date:5/20/2013)... May 20, 2013 Nearly 20 percent of kidneys ... are refused for transplant due to factors ranging from ... units to the organ going too long without blood ... these organs could be "recycled" to help solve the ... Forest Baptist Medical Center and colleagues, reporting in the ...
(Date:5/20/2013)... 2013 Horizon NJ Health, New Jersey’s ... that it has earned a Commendable Accreditation status ... NJ Health is a wholly owned subsidiary of Horizon ... NCQA Health Plan Accreditation is a nationally recognized program ... health plans provide to their members. Health Plan Accreditation ...
Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:Study suggests new source of kidneys for transplant 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
... ,Kick Butts Day, at 11 a.m. in Kettering, ... leaders from Ohio will hold a press conference on,Wednesday, ... how tobacco,companies take advantage of the lack of government ... aimed at hooking kids and,preventing current smokers from quitting. ...
... MIAMI, March 31 According to the World ... blacks, but,many Latinos and a few elderly Whites ... total incurable Glaucoma-Blindness,("White-Canes"). Most lack the opportunity to ... them of all their sight. Dr. Robert,Welsh, a ...
... highlights research on Blue Cross ... care utilization, EAGAN, Minn., March 31 In ... Quarterly, Blue Cross and Blue,Shield of Minnesota (Blue Cross) ... percent fewer visits to the emergency room and,had an ...
... 17,000 people with coronary artery disease or diabetes , , ... ACE inhibitor drug was as effective in reducing deaths, ... patients as a newer and more expensive angiotensin-receptor blocker ... The study of more than 17,000 people with coronary ...
... (Baltimore, MD) On April 2, the Kennedy Krieger ... Awareness Month with the one-year anniversary of the Interactive ... Launched in April 2007 by the Kennedy Krieger Institute, ... of causes, treatments, and the search for a possible ...
... Those Living with Epilepsy, TITUSVILLE, N.J., March 31 ... It has the ability to relay our deepest feelings ... strokes. For people,with epilepsy, art can be a valuable ... serious neurological condition., The sixth annual Expressions of ...
Cached Medicine News:Health News:Ohio Faith Leaders Call on Sen. Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 2Health News:New Welsh 'Self-Test' to Cure Glaucoma, the Leading Cause of Preventable Blindness 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 3Health News:ACE Inhibitor as Effective as More Expensive Blood Pressure Drug 2Health News:First national autism registry shows notable impact on autism research in opening year 2Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 2Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 3Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 4
Ahmed Glaucoma Valve (small size) with Pars Plana Clip ....
Ahmed Glaucoma Valve....
... biocompatibility is established. Provides a robust and ... correct positioning on the globe. Pressure Ridge ... when covered by Tenons tissue, acts as ... hypotony. The range of implants allows the ...
... Goldmann standard automatic or manual kinetic ... white/white, blue/yellow or red/white stimuli/background colors. ... classic 4-2 threshold strategy. Examination with ... (including 30-2, 24-2, and 10-2). Gray-scale/ ...
Medicine Products: